康宁杰瑞制药-B(09966.HK) 公布,JSKN016的双特异性抗体偶联药物(ADC(s))用于治疗三阴性乳腺癌(TNBC)的一项III期临床研究已成功完成首例患者给药。(ca/da)(港股报价延迟最少十五分钟。沽空资料截至 2026-03-19 16:25。)AASTOCKS新闻
Source Link康宁杰瑞制药-B(09966.HK) 公布,JSKN016的双特异性抗体偶联药物(ADC(s))用于治疗三阴性乳腺癌(TNBC)的一项III期临床研究已成功完成首例患者给药。(ca/da)(港股报价延迟最少十五分钟。沽空资料截至 2026-03-19 16:25。)AASTOCKS新闻
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.